Leave Your Message
Blog Categories
Featured Blog
Oncolytic virus technology for the treatment of melanoma

Oncolytic virus technology for the treatment of melanoma
The world's first CD7 CAR-T therapy

The world's first CD7 CAR-T therapy
Small molecule innovative drug with brain-penetrant-resistant mutant FGFR2/3 inhibitors (novel chemical structure irreversible inhibitors).

Small molecule innovative drug with brain-penetrant-resistant mutant FGFR2/3 inhibitors (novel chemical structure irreversible inhibitors).
High brain-penetrant microtubule stabilizers (MSA)

High brain-penetrant microtubule stabilizers (MSA)
FIC EP2/EP4 dual antagonist

FIC EP2/EP4 dual antagonist
USP1 (Ubiquitin-Specific Peptidase 1) inhibitor

USP1 (Ubiquitin-Specific Peptidase 1) inhibitor
0102030405

The world's first CD7 CAR-T therapy

2024-07-19
  • Program：The world's first CD7 CAR-T therapy
  • Indication:  Refractory/relapsed T-cell lymphoblastic leukemia/lymphoma 
  • Status：China: Phase II clinical trial is about to start; USA: Granted FDA orphan drug designation; EU: Granted orphan drug designation by the European Commission
  • Collaboration Opportunity: Licensing collaboration/co-development; investment and financing
  • Highlights：
  • The CD7-targeted CAR-T therapy has high technical barriers, with few companies currently positioned in this field, providing a significant competitive advantage.
  • Innovatively using a non-gene editing strategy and the nanobody VHH6, normal T lymphocytes from the patient's own peripheral blood are modified with CAR and then reinfused into the patient, avoiding the risk of GVHD.
  • Excellent Phase I clinical results: A total of 12 refractory relapsed patients were treated; significant antitumor efficacy was observed in all dose groups; ORR = 83%, CR = 75%, 3M DOR = 66.7%.